
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. has demonstrated robust financial health, with a 23% year-over-year revenue increase, reaching $46.4 million in Q2 2025. The company also achieved a notable improvement in gross margin, increasing approximately 80 basis points year-over-year to 79.8%. Furthermore, the positive momentum is reflected in an upward revision of the 2025 revenue estimate to $196.5 million, bolstered by strong performance in Q2 and enhanced sales productivity.
Bears say
The analysis highlights fundamental concerns regarding SI-BONE Inc.'s stock due to ongoing challenges within the global spine market, which has been experiencing low-single-digit growth attributed to pricing and procedural headwinds. Furthermore, the company faces potential market share erosion in the sacroiliac joint fusion market if payors opt to reimburse competitive products, which could significantly impact its revenue. Finally, SI-BONE's enterprise value to sales growth ratio of 0.19x is considerably lower than the median of 0.34x for its small to mid-cap growth peers, indicating a lack of investor confidence in its growth prospects compared to competitors.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares